Search

Your search keyword '"de Vos D"' showing total 754 results
Start Over Author "de Vos D"
754 results on '"de Vos D"'

57. Abstracts of papers clinical pharmacological meeting

Author

van Harten, J., Burggraaf, J., Danhof, M., van Brummelen, P., Breimer, D. D., Lenders, J. W. M., Morre, H., Thien, Th., de Leeuw, P. W., van ES, P. N., de Bos, R., Birkenhäger, W. H., Cohen, A. F., Posner, J., Harkin, N., van Meijel, J. J. M., Gerlag, P. G. G., Gribnau, F. W. J., Blauw, G. J., van Bnnmelen, P., Vermelj, P., van Zwieten, P. A., van der Voet, G. B., Tebeest, L. G., Stewart, F. A., Bartelink, H., de Wolff, F. A., de Vos, D., Salemans, J., Hoitsma, A. J., de Abreu, R. A., Koene, R. A. P., van den Ouweland, F., van Vliet-Daskalopoulou, E., Wijnand, H. P., van de Putte, L. B. A., Eijsbouts, A., Smits, P., Festen, J., Houben, J. G. G., Folgering, H., Meulenberg, P. M. M., Koopmans, P. P., van Megen, Th., Dunselman, P. H. J. M., Scaf, A. H. J., Kuntze, C. E. E., Lie, K. I., Wesselinq, H., Holtslag, J. C. W. M., Moshage, H. J., van Pelt, J. F., Kleuskens, J. A. G. M., and Yap, S. H.

Published
1987
Full Text
View/download PDF

59. Abstracts of papers clinical pharmacological meeting

Author

Merkus, F. W. H. M., Gribnau, F. W. J., Thien, Th., Louwerenburg, Hans W., Kingma, J. Herre, van Gilst, Wiek H., Six, A. Jacob, de Graeff, Pieter, Wesseling, Harry, BoeLaert, J. R., Schurgers, M. L., Matthys, E. G., Belpaire, F., Daneels, R. F., de Cre, M. J., Boqaert, M. G., D'Haese, P. C., Verpooten, G. A., Lamberts, L. V., Liang, L., de Broe, M. E., de Meijer, P. H. E. M., Russel, F. G. M., Russel, A. J. M., van Ginneken, C. A. M., van Liedekerke, B. M., Lambert, W. E., Yousouf, M. A., de Roose, J. E., de Leenheer, A. P., Lambert, W., de Bersaques, J., Vanneste, L., de Leenheer, A., de Marie, S., Slaghuis, G., Rozing, P. M., Mattie, H., Poelma, F. G. J., Hilbers, H. W., Jansen, A. C. A., Tukker, J. J., Augusti, Jr, P., Verbeke, N., van Peer, A., Snoeck, E., Heykants, J., Bruynseels, J., Peeters, J., Amery, W., Rogiers, V., Vandenberghe, Y., Comet, M., Callaerts, A., Sonck, W., Guillouzo, A., Vercruysse, A., van Rooy, P., Rombaut, N., vanden Bussche, G., Tan, A. C. I. T. L., Jansen, T. L. Th. A., Termond, E. F. S., Kloppenborg, P. W. C., Thien, Th., Benraad, Th. J., van de Velde, V., Woestenbprghs, R., Hermens, W. A. J. J., Romeijn, S. G., Deurloo, M. J. M., Merkus, F. W. H. M., Musch, G., Massart, D. L., van Hengstum, M., Festen, J., van den Broek, W., Corstens, F., Beurskens, C., Hankel, M., de Smet, M., van Belle, S. J. P., de May, J., Storme, G. A., Kuppen, P. J. K., Schuitemaker, H., Veer, L. J. van't, van Oosterom, A. T., Schrier, P. I., de Bruijn, E. A., de Pooter, C. H., Tjaden, U. R., van Slooten, H., Roelevink, H. P., Smit, E., de Vries, E. G. E., Ijmker, J., Uges, D. R. A., Moors, M., Mertens, K., van Hecken, A., de Lepeleire, I., Verbesselt, R., Tjandra-Maga, T. B., de Schepper, P. J., Guelen, P. J. M., Jansen, T. J., Vrijhof, W. P., de Vos, D., Scharpé, S., Verkerk, R., Lsmeire, N., Zijlstra, I. F., Gribnau, F. W. J., Haaijer-Ruskamp, F. M., Post, D., Reddingius, P. F., Wesseling, H., Wollersheim, H. C. H., van den Meiracker, A. H., Veld, A. J. Man in 't, Admiraal, P., Boomsma, F., Derkx, F., Schalekamp, M. A. D. H., Schoors, D. F., Dupont, A. G., Claessen, F., Reljenga, J., Lenders, J. W. M., Thlen, Th., Laekeman, G., Muylle, L., van Hoydonck, A., Herman, A. G., and Peetermans, M. E.

Published
1988
Full Text
View/download PDF

61. Abstracts of papers Clinical Pharmacological meeting

Author

van Meyel, J. J. M., Smits, P., Gribnau, F. W. J., Van Bortel, L. H. A. B., van Herode, T., Smeets, F. A. H., Reneman, R. S., Struyker Boudler, H. A. J., Aengevaeren, W., Corstens, F., v. d. Werf, T., Thien, Th., Buijsrogge, J -P. H. C., Thien, Th, Hooymans, P. M., Pouwels, M. J., v. d. Aa, G. C. H. M., Pouwbls, M. J., Diepstraten, J. M. W. J., Koopmans, P. P., van der Aa, G. C. H. M., Leeuwenkamp, O. R., Van Per Wiel, H. E., van der Vijgh, W. J. F., Greuter, H., Barto, R., Netelenbos, J. C., Lips, P., de Vos, D., Siee, P. H. Th. J., Stevenson, D., de Vos, P., Slee, P. H. Th. J., Ooslerhuis, B., Nehmiz, G., Cornelissen, P. J. G., Zuiderwijk, P. B. M., Jeuring, H. J., Jonkman, J. H. G., Su, C. A. P. F., van Tol, R. G. L., van Riel, A., Kerremans, A. L. H., van Kalken, C. K., de Jong, J., van der Hoeven, J. J. M., van der Vijgh, W. J. F., Pinedo, H. M., Kroon, C., de Boer, A., van der Meer, F. J. M., Edelbroek, P. M., Schoemaker, H. C., Cohen, A. F., van Steveninck, A. L., Kroon, J. M., Pieters, M. S. M., Breimer, D. D., Tukker, J. J., and Mculendijk, A. J. M.

Published
1989
Full Text
View/download PDF

62. Abstracts of papers clinical pharmacological meeting

Author

van den Ouweland, F. A., Eenhoorn, P. C., Tan, Y., Gribnau, F. W. J., van Brupgen, A., de Graeff, P. A., van den Toren, E. W., van Gilst, W. H., Wesseling, H., Lie, K. I., Postula, C. T., Hoefnagels, W. B. L., de Boo, Th., Thien, Th., Boon E. S., Goyskes, C. G., Boor, P., van Schalk, B. A. M., Abma, C., Frijns, T. R. J. A., Wamer, J., Elving, L. D., de Nobel, E., Mattie, H., van Gulpen, C., Lammers, J-W. J., Minette, P., Barnes, P. J., Jongejan, R. C., de Jongste, J. C., Raatgeep, H. C., Bonta, I. L., Kerrebijn, K. F., Mol, M. J., Stalenhoef, A. F., Stuyt, P. M., van 't Laar, A., Ermens, A. A. M., Schoester, M., Lindemans, J., Abels, J., van Baak, M. A., Mooij, J. M. V., Schiffers, P. M. H., Wetzels, J. F. M., v. Berqeyk, J. D., v. Heusden, F. H. J. A., Huysmans, F. Th. M., Hoitsma, A. J., Koene, R. A. P., Jansen, H. M. L., Russel, F. G. M., Wouterse, A. C., van Ginneken, C. A. M., Pol, Y. W. A. v. d., de Vries, E. G. E., Greidanus, J., Mulder, N. H., Sleijfer, D. Th., Willemse, P. H. B., Uges, D. R. A., Smits, P. A. B. M., Louwerenburg, J. W., Kingma, J. H., IJdenberg, F. N., Poelma, F. G. J., Breŝ, R., Tukker, J. J., Remmert, H. P., Olling, M., Slob, W., van der Giesen, W., Rauws, A. G., Runhaar, E. A., Neijt, J. P., Holthuis, J. J. M., de Vos, D., Tukker, J J, Poelma, F G J, Thijssen, H. H. W., Hamulyák, K., Franssen, C., Wollersheim, H., Jansen, R. W. M. M., van Lier, H. J. J., Hoefnagels, W. H. L., Grgen, C., Horan, M-A., Oomerjee, Z. A. R., Breimer, D. D., van Bezooijen, C. F. A., Keizer, H. J., Cleton, F. J., de Bruijn, E. A., Tiaden, U. R., de Boer, A., Stiekema, J. C. J., and Danhof, M.

Published
1988
Full Text
View/download PDF

64. Evaluation of a microbiological screening and acceptance procedure for cryopreserved skin allografts based on 14 day cultures

Author

Pirnay, Jean-Paul, Verween, G., Pascual, B., Verbeken, Gilbert, De Corte, P., Rose, T., Jennes, S., Vanderkelen, Alain, Marichal, Miriam, Heundrickx, Walter, De Vos, D., Hosp, Queen Astrid Mil, Bank, Human Cell, Brussels, [No Value], Belgium, [No Value], Surgical clinical sciences, Specialities, Skin function and permeability, Vriendenkring VUB, Surgery, Pathological Anatomy, and Diabetes Pathology & Therapy

Subjects
integumentary system, preservation, bank, donor skin, immunogenecity
Abstract

Viable donor skin is still considered the gold standard for the temporary covering of burns. Since 1985, the Brussels military skin bank supplies cryopreserved viable cadaveric skin for therapeutic use. Unfortunately, viable skin can not be sterilised, which increases the risk of disease transmission. On the other hand, every effort should be made to ensure that the largest possible part of the donated skin is processed into high-performance grafts. Cryopreserved skin allografts that fail bacterial or fungal screening are reworked into 'sterile' non-viable glycerolised skin allografts. The transposition of the European Human Cell and Tissue Directives into Belgian Law has prompted us to install a pragmatic microbiological screening and acceptance procedure, which is based on 14 day enrichment broth cultures of finished product samples and treats the complex issues of 'acceptable bioburden' and 'absence of objectionable organisms'. In this paper we evaluate this procedure applied on 148 skin donations. An incubation time of 14 days allowed for the detection of an additional 16.9% (25/148) of contaminated skin compared to our classic 3 day incubation protocol and consequently increased the share of non-viable glycerolised skin with 8.4%. Importantly, 24% of these slow-growing microorganisms were considered to be potentially pathogenic. In addition, we raise the issue of 'representative sampling' of heterogeneously contaminated skin. In summary, we feel that our present microbiological testing and acceptance procedure assures adequate patient safety and skin availability. The question remains, however, whether the supposed increased safety of our skin grafts outweighs the reduced overall clinical performance and the increase in work load and costs.

Published
2012

65. Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine

Author

Verbeken, Gilbert, Pirnay, Jean-Paul, De Vos, D., Jennes, S., Zizi, Martin, Lavigne, R., Casteels, Minne, Hosp, Queen Astrid Mil, Mol, Lab, Surgical clinical sciences, Specialities, Skin function and permeability, and Vriendenkring VUB

Subjects
therapy, european, bacteriophage, legatory, Human, legal
Abstract

For practitioners at hospitals seeking to use natural (not genetically modified, as appearing in nature) bacteriophages for treatment of antibiotic-resistant bacterial infections (bacteriophage therapy), Europe's current regulatory framework for medicinal products hinders more than it facilitates. Although many experts consider bacteriophage therapy to be a promising complementary (or alternative) treatment to antibiotic therapy, no bacteriophage-specific framework for documentation exists to date. Decades worth of historical clinical data on bacteriophage therapy (from Eastern Europe, particularly Poland, and the former Soviet republics, particularly Georgia and Russia, as well as from today's 27 EU member states and the US) have not been taken into account by European regulators because these data have not been validated under current Western regulatory standards. Consequently, applicants carrying out standard clinical trials on bacteriophages in Europe are obliged to initiate clinical work from scratch. This paper argues for a reduced documentation threshold for Phase 1 clinical trials of bacteriophages and maintains that bacteriophages should not be categorized as classical medicinal products for at least two reasons: (1) such a categorization is scientifically inappropriate for this specific therapy and (2) such a categorization limits the marketing authorization process to industry, the only stakeholder with sufficient financial resources to prepare a complete dossier for the competent authorities. This paper reflects on the current regulatory framework for medicines in Europe and assesses possible regulatory pathways for the (re-)introduction of bacteriophage therapy in a way that maintains its effectiveness and safety as well as its inherent characteristics of sustainability and in situ self-amplification and limitation.

Published
2012

66. The Phage Therapy Paradigm: Prt-A -Porter or Sur-mesure?

Author

Pirnay, Jean-Paul, De Vos, D., Verbeken, Gilbert, Merabishvili, M., Chanishvili, M., Vaneechoutte, M, Zizi, Martin, Laire, G., Lavigne, R., Van Den Mooter, Guy, Buckling, Angus, Debarbieux, Laurent, Pouillot, Flavie, Azedo, Joanna, Kutter, Elisabeth, Dublanchet, Alain, Gorski, Andrezje, Adamia, Revaz, Louvain, Catholic Univ, Pharmacotechnol, Lab, Surgical clinical sciences, Specialities, and Skin function and permeability

Subjects
antibiotic resistance, Bacterial Infections
Abstract

not available

Published
2011

69. Woord vooraf

Author

op 't Hof, W.J., de Vos, D., Faculty of Religion and Theology, and Church History

Published
2007

77. Base catalytic activity of alkaline earth MOFs: a (micro)spectroscopic study of active site formation by the controlled transformation of structural anions

Author

Valvekens, P., primary, Jonckheere, D., additional, De Baerdemaeker, T., additional, Kubarev, A. V., additional, Vandichel, M., additional, Hemelsoet, K., additional, Waroquier, M., additional, Van Speybroeck, V., additional, Smolders, E., additional, Depla, D., additional, Roeffaers, M. B. J., additional, and De Vos, D., additional

Published
2014
Full Text
View/download PDF

79. Business strategies and the transition to low-carbon cities

Author

Whiteman, Gail, de Vos, D. Rene, Chapin, F. Stuart, Yli-Pelkonen, Vesa, Niemela, Jari, Forbes, Bruce C., Whiteman, Gail, de Vos, D. Rene, Chapin, F. Stuart, Yli-Pelkonen, Vesa, Niemela, Jari, and Forbes, Bruce C.

Abstract

Cities are key drivers of global climate change, with the majority of greenhouse gas (GHG) emissions being tied to urban life. Local actions to mitigate and adapt to climate change are essential for stabilization of the global climate and can also help to address other urban ecological problems such as pollution, decreasing biodiversity, etc. Companies are important urban actors in the development of low-carbon cities because they provide a multitude of goods and services to city populations and directly influence urban carbon dioxide (CO2) emissions. This is a new area of research. While studies on corporate sustainability are numerous, there is little, if any, existing research that examines the role of companies in climate change adaptation and mitigation within specific urban areas. Urban ecologists also have not examined how corporate activity affects urban systems. Taking a multi-disciplinary systems approach, we present a conceptual model of the role of companies in managing urban interactions with the climate system. We also present empirical findings illustrating how one company ‘partners’ with the city of Rotterdam to test electric vehicles as a pilot project for urban climate adaptation and mitigation.

Published
2011

80. Amino acetate functionalized Schiff base organotin(IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies

Author

Basu Baul, T S, Basu, S, De Vos, D, Linden, Anthony; https://orcid.org/0000-0002-9343-9180, Basu Baul, T S, Basu, S, De Vos, D, and Linden, Anthony; https://orcid.org/0000-0002-9343-9180

Abstract

Potassium 2-{[(2Z)-(3-hydroxy-1-methyl 2-butenylidene)]amino}-4-methyl-pentanoate (L1HK) and potassium 2-{[(E)-1-(2-hydroxyphenyl)alkylidene]amino}-4-methyl-pentanoates (L2HK-L3HK) underwent reactions with PhnSnCl4-n (n = 2 and 3) to give the amino acetate functionalized Schiff base organotin(IV) complexes [Ph3SnLH]n (1-3) and [Ph2SnL] (4), respectively. These complexes have been characterized by 1H, 13C, 119Sn NMR, IR spectroscopic techniques in combination with elemental analyses. The crystal structures of 1 and 3 were determined. The crystal structures reveal that the complexes exist as polymeric chains in which the L-bridged Sn-atoms adopt a trans-R3SnO2 trigonal bipyramidal configuration with the Ph groups in the equatorial positions and the axial locations occupied by a carboxylate oxygen atom from one carboxylate ligand and the alcoholic or phenolic oxygen atom of the next carboxylate ligand in the chain. The carboxylate ligands coordinate in the zwitterionic form with the alcoholic/phenolic proton moved to the nearby nitrogen atom. The solution structures were predicted by 119Sn NMR spectroscopy. When these organotin(IV) complexes were tested against A498, EVSA-T, H226, IGROV, M19 MEL, MCF7 and WIDR human tumor cell lines, the average ID50 values obtained were 55, 80 and 35 ng/ml for triphenyltin(IV) compounds 1-3, respectively. The most cytotoxic triphenyltin(IV) compound in the present report (3) with an average ID50 value of around 35 ng/ml is found to be morer cytotoxic for all the cell lines studied than doxorubicin, cisplatin, 5-fluorouracil and etoposide.

Published
2009

83. 135 The use of rep-PCR (Diversilab, bioMerieux) in combination with multiplex PCR (targeting virulence genes) reveals the transmission of Pseudomonas aeruginosa isolates among cystic fibrosis patients in a hospital background

Author

Dingemans, J., primary, Craggs, M., additional, Bilocq, F., additional, Willekens, J., additional, Eyns, H., additional, Crabbé, A., additional, De Vos, D., additional, Pirnay, J.-P., additional, Malfroot, A., additional, and Cornelis, P., additional

Published
2013
Full Text
View/download PDF

84. Fast Fourier-Transform Second-Harmonic Generation (FFT-SHG) Provides a Solution for Measuring Nonlinear Effects on Fragile Structures

Author

Vanbel, M. K., primary, Paesen, R., additional, Brullot, W., additional, Vandendriessche, S., additional, Asselberghs, I., additional, Markey, K., additional, Valvekens, P., additional, van der Veen, M. A., additional, De Vos, D., additional, Ameloot, M., additional, Valev, V. K., additional, Locquet, J.-P., additional, and Verbiest, T., additional

Published
2013
Full Text
View/download PDF

87. Multi drug resistant (MDR) Acinetobacter baumannii outbreak in the Brussels burn wound centre

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, De Vos, D., Pieters, Thierry, Glupczynski, Gerald, Bogaerts, Pierre, Dijkshoorn, L., van der Reijden, T. J. K., Bilocq, F., Vaneechoutte, M., Bosmans, P., Soentjens, P., Pirson, Joseph, Pimay, J. -P., UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, De Vos, D., Pieters, Thierry, Glupczynski, Gerald, Bogaerts, Pierre, Dijkshoorn, L., van der Reijden, T. J. K., Bilocq, F., Vaneechoutte, M., Bosmans, P., Soentjens, P., Pirson, Joseph, and Pimay, J. -P.

Published
2007

90. Thermally injured and Acinetobacter baumannii colonizations/infections during a five-year period at the Brussels Burn Wound Centre

Author

De Vos, D., primary, Bilocq, F., additional, Verbeken, G., additional, Pieters, T., additional, Dijkshoorn, L., additional, Bogaerts, P., additional, Glupczynski, Y., additional, Deschaght, P., additional, Heuninckx, W., additional, Bosmans, P., additional, Vaneechoutte, M., additional, Rose, T., additional, Pot, B., additional, van der Reijden, T.J., additional, Pirnay, J.-P., additional, Jennes, S., additional, and soentjens, P., additional

Published
2012
Full Text
View/download PDF

92. Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] [L=o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]

Author

R¿ntgenparticipatieprogramma, Universiteit Utrecht, Dep Scheikunde, Hotze, A.C.G., Caspers, S.E., de Vos, D., Kooijman, H., Spek, A.L., Flamigni, A., Bacac, M., Sava, G., Haasnoot, J.G., Reedijk, J., R¿ntgenparticipatieprogramma, Universiteit Utrecht, Dep Scheikunde, Hotze, A.C.G., Caspers, S.E., de Vos, D., Kooijman, H., Spek, A.L., Flamigni, A., Bacac, M., Sava, G., Haasnoot, J.G., and Reedijk, J.

Published
2004

94. Meeting report on the 8th International Symposium on Scientific Bases for the Preparation of Heterogeneous Catalysts, Louvain-la-Neuve (Belgium), September 9-12, 2002

Author

UCL - AGRO/CABI - Département de chimie appliquée et des bio-industries, KULeuven - Centre voor Oppervlaktechemie en Katalyse, Gaigneaux, Eric M., De Vos, D., Grange, Paul, Jacobs, P.A., Martens , J., Ruiz, Patricio, Poncelet, Georges, UCL - AGRO/CABI - Département de chimie appliquée et des bio-industries, KULeuven - Centre voor Oppervlaktechemie en Katalyse, Gaigneaux, Eric M., De Vos, D., Grange, Paul, Jacobs, P.A., Martens , J., Ruiz, Patricio, and Poncelet, Georges

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results